Related Experiment Video
Updated: May 7, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.6K
Updates on Patent Foramen Ovale (PFO) Closure
Konstantinos V Voudris1, Marie-France Poulin2, Clifford J Kavinsky3
1Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Minneapolis, MN, USA.
Current Cardiology Reports
|June 24, 2024
Summary
Patent foramen ovale (PFO) closure is recommended for cryptogenic stroke, with new devices improving outcomes. Further research is needed for specific patient groups and conditions like migraines.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Patent foramen ovale (PFO) is associated with left circulation thromboembolism and stroke.
- Understanding PFO's role in various conditions is crucial for effective treatment.
Purpose of the Study:
- To review the latest evidence on PFO closure.
- To discuss updated guidelines, diagnostic tools, and novel devices for PFO closure.
Main Methods:
- Literature review of recent studies and societal guidelines.
- Analysis of diagnostic algorithms and risk stratification tools.
- Evaluation of emerging therapeutic devices for PFO closure.
Main Results:
- PFO closure is strongly recommended for cryptogenic stroke and systemic embolization.
- Evidence supports PFO closure for platypnea-orthodeoxia syndrome.
- Current data do not support routine PFO closure for migraines or decompression illness.
- Novel devices are under evaluation to enhance safety and efficacy.
- PFO closure shows superiority in reducing recurrent embolic stroke risk in select patients.
Conclusions:
- PFO closure is a valuable therapeutic option for specific thromboembolic conditions.
- Heart-brain teams and advanced algorithms can optimize patient selection.
- Continued research is necessary to refine patient selection and treatment strategies for subgroups.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...